Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Vericiguat in Hepatic Impairment
NCT04722562Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (3 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve of vericiguat up to 96 hours, Area Under the Curve unbound of vericiguat up to 96 hours and 2 more. Started Jul 2014; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04722562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722562.